Skip to Main Content

Roy H. Decker, MD/PhD

Professor of Therapeutic Radiology

Contact Information

Roy H. Decker, MD/PhD

Office Location

Mailing Address

  • Therapeutic Radiology

    PO Box 208040

    New Haven, CT 06520-8040

    United States

Research Summary

I am a radiation oncologist focusing on the treatment of lung cancer and head and neck cancer, working at the Yale University School of Medicine, and the Smilow Cancer Hospital at Yale New Haven. I am a member of the Cancer Center’s Radiobiology & Radiotherapy Program. For early lung cancer, my research focus is based on the treatment of stage I or II NSCLC with SBRT. For advanced cancer, my research focus has been the addition of targeted agents concurrently with fractionated radiation, in an effort to increase the tumor radiation response, and in combining radiation with immunotherapy in metastatic disease.

Coauthors

Research Interests

Carcinoma, Non-Small-Cell Lung; Lung; Medical Oncology; Neoplasm Metastasis; Radiotherapy

Selected Publications

Clinical Trials

ConditionsStudy Title
LungA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
ProstatePhase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Larynx; Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Larynx; Lip, Oral Cavity and PharynxRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer